A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Status:
Completed
Trial end date:
2020-02-13
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to investigate the safety of prexasertib in combination
with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in
participants with advanced cancer or cancer that has spread to another part of the body. The
study has multiple parts (A, B, C, D and E). Participants will only enroll in one part.